Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep225 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

The effect of obesity on the association between type 2 diabetes mellitus and polycystic ovary syndrome: a meta-analysis of observational studies

Anagnostis Panagiotis , Paparodis Rodis , Bosdou Julia , Bothou Christina , Macut Djuro P. , Goulis Dimitrios , Livadas Sarantis

ObjectiveThe exact risk of type 2 diabetes in women with polycystic ovary syndrome (PCOS) is unknown. It is also unclear if obesity independently increases the risk in this population. The aim of this study was to systematically review and synthesize the best available evidence regarding the association between PCOS and type 2 diabetes, stratified according to obesity status.MethodsA comprehensive search was ...

ea0081rc13.4 | Rapid Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Analysis of the body composition and glucose metabolism in relation to bcli glucocorticoid receptor polymorphism in women with adrenal incidentalomas

Ognjanovic Sanja , Popovic Bojana , Ilic Dusan , Elezovic Valentina , Antic Jadranka , Opalic Milica , Radic Lena , Macut Djuro P

Single nucleotide polymorphisms in the glucocorticoid receptor (GR) gene influence tissue sensitivity of GR. Several studies have shown different effects of BclI GR polymorphism on body composition and metabolic parameters. The objective of this study was to explore the effect of BclI GR polymorphism on the body composition and glucose metabolism. Biochemical tests and hormonal evaluation were performed in 106 consecutive women with adrenal incidentalomas (AI...

ea0081p665 | Pituitary and Neuroendocrinology | ECE2022

Long-term follow up after remission of Cushing’s disease - experience of a single centre

Popovic Bojana , Ognjanovic Sanja , Ilic Dusan , Elezovic Valentina , Opalic Milica , Radic Lena , Milicevic Mihailo , Macut Djuro P.

Introduction: Chronic endogenous hypercortisolism in CushingÂ’s syndrome imposes a great clinical burden of comorbidities, some of which might persist even after disease remission. Our aim was to analyze factors that predict long-term comorbidities after surgical remission of CushingÂ’s disease (CD).Subjects and methods: We retrospectively analyzed 37 patents (91.9% females) aged 39.5±13.9 years (10-70) with diagnosed CD, treated in our inst...

ea0081ep903 | Reproductive and Developmental Endocrinology | ECE2022

Clinical utility of the Anti-Mullerian Hormone testing for the prediction of PCOS

Soldat Stankovic Valentina , Pejicic Snjezana Popovic , Grbic Aleksandra , Dojcinovic Tamara , Malesevic Gabrijela , Brkic Milena , Macut Djuro P.

Introduction: The diagnostic criteria of polycystic ovary syndrome (PCOS) are still under discussion and the hormonal parameters, including anti-Mullerian hormone range and hyperandrogenism, are not determined. Serum AMH level has been proposed as a surrogate marker for PCOM and could, therefore, be integrated in the diagnostic classifications for PCOS\. The aim of the present study was to characterize hormonal features of PCOS and to establish the most important hormonal para...

ea0081ep889 | Reproductive and Developmental Endocrinology | ECE2022

Association of SPISE and HOMA-IR indexes with metabolic characteristics of different age groups of women with polycystic ovary syndrome

Opalic Milica , Ognjanovic Sanja , Popovic Bojana , Ilic Dusan , Bjekic - Macut Jelica , Elezovic Valentina , Radic Lena , Milutinovic Danijela Vojnovic , Stanojlovic Olivera , Macut Djuro P.

Introduction: Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among women during reproductive age. PCOS cardinal manifestations include hyperandrogenism, oligo/anovulation, and/or polycystic ovarian morphology, and is closely linked to metabolic disorders such as obesity and insulin resistance (IR). It was observed that single-point insulin sensitivity estimator (SPISE) index is associated with metabolic abnormalities and could predict glucose regulation ...

ea0081oc4.3 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Long-term efficacy and safety data for oral octreotide capsules in acromegaly: mpowered trial open-label extension phase

Fleseriu Maria , Molitch Mark E , Dreval Alexander , Pokramovich Yulia G , Bondar Irina , Poteshkin Yury E , Macut Djuro P , Obermayer-Pietsch Barbara , Gilgun-Sherki Yossi , Haviv Asi , Biermasz Nienke , Melmed Shlomo , Strasburger Christian J

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.Objective:...

ea0073oc13.6 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands

Fleseriu Maria , Dreval Alexander V. , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E. , Macut Djuro P. , Leonova Nina , Raverot Gerald , Grineva Elena , Poteshkin Yury E. , Gilgun-Sherki Yossi G , Ludlam William H. , Patou Gary , Haviv Asi , Gordon Murray B. , Biermasz Nienke , Melmed Shlomo K. , Strasburger Yossi G

BackgroundMPOWERED, a large phase 3 trial, assessed maintenance of response to oral octreotide capsules (OOC; MYCAPSSA) compared to injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly who responded to OOC and iSRLs (octreotide or lanreotide). OOC were recently approved in the US for patients with acromegaly who responded to and tolerated iSRLs.MethodsEligibility criteria included age ...

ea0073pep3.2 | Presented ePosters 3: Pituitary and Neuroendocrinology | ECE2021

Safety results from MPOWERED, a phase 3 trial of oral octreotide capsules in adults with acromegaly

Freda Pamela U. , Fleseriu Maria , Dreval Alexander V. , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Huang Wenyu , Molitch Mark E. , Macut Djuro P. , Leonova Nina , Raverot Gerald , Yossi Gilgun-Sherki , Ludlam William H. , Patou Gary , Haviv Asi , Gordon Murray B. , Biermasz Nienke , Melmed Shlomo K. , Strasburger Christian J.

BackgroundInjectable somatostatin receptor ligands (iSRLs) have been a mainstay in acromegaly treatment. Oral octreotide capsules (OOC; MYCAPSSA®) were recently approved in the USA. Results from the placebo-controlled CHIASMA OPTIMAL and open-label CH-ACM-01 studies showed an OOC safety profile consistent with that of iSRLs with no new or unexpected safety signals. Results of the MPOWERED trial have enabled a comparison of OOC safety and ...

ea0073pep8.1 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Oral octreotide capsules lowered incidence and improved severity of acromegaly symptoms compared to injectable somatostatin receptor ligands—results from the MPOWERED trial

Biermasz Nienke , Fleseriu Maria , Dreval Alexander V , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E , Macut Djuro P , Leonova Nina , Raverot Gerald , Yossi Gilgun-Sherki , Ludlam William H , Patou Gary , Haviv Asi , Gordon Murray B , Urbanavicius Vaidotas , Knispelis Robertas , Melmed Shlomo K , Strasburger Christian J

BackgroundPatients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA®) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been first-line medical treatment for patients with acromegaly for decades. OOC are newly approved in the US for patients previously controlled on iSRL...

ea0073pep8.3 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy

Fleseriu Maria , Dreval Alexander V. , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E. , Macut Djuro P. , Leonova Nina , Raverot Gerald , Yossi Gilgun-Sherki , Ludlam William H. , Patou Gary , Haviv Asi , Gordon Murray B. , Verbovoy Andrey , Dogadin Sergey A. , Biermasz Nienke , Strasburger Christian J. , Melmed Shlomo K.

BackgroundOral octreotide capsules (OOC; MYCAPSSA®) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately controlled with iSRLS.1 The phase 3 MPOWERED trial assessed maintenance of response with OOC compared to iSRLs. Patients receiving OOC and in...